The company raised its full-year earnings guidance to $4.65 to $4.75 a share on a non-GAAP basis vs. a previous estimate of $4.50 to $4.65 a share. Analysts, on average, were expecting earnings of $4.61 a share.
For the third quarter, Eli Lilly posted a net income increase of 38% to $1.302 billion, or $1.18 a share, from $941.8 million, or 86 cents, the previous year, amid continued cost reduction. Adjusted earnings were $1.21 a share.
Revenue rose 2% to $5.655 billion from $5.562 billion.
The Wall Street consensus estimate for the quarter was earnings of $1.15 a share on revenue of $5.79 billion.
Eli Lilly shares were higher by 1.4% to $36.51 in premarket trading Thursday.
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.